Cytokinetics Inc. Stock
Price
Target price
€75.70
€75.70
5.140%
3.7
5.140%
€81.65
17:31 / Tradegate
WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cytokinetics Inc. Stock
Cytokinetics Inc. dominated the market today, gaining €3.70 (5.140%).
With 42 Buy predictions and not a single Sell prediction Cytokinetics Inc. is an absolute favorite of our community.
With a target price of 81 € there is a slightly positive potential of 7.0% for Cytokinetics Inc. compared to the current price of 75.7 €.
So far the community has only identified positive things for Cytokinetics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | 5.140% | 5.079% | 8.466% | 153.521% | 34.579% | 133.766% | 282.979% |
| Heron Therapeutics Inc. | 2.100% | 2.700% | -52.419% | -79.761% | -66.535% | -66.109% | -97.319% |
| Evolus Inc | 0.100% | 10.191% | 18.223% | -19.117% | 14.275% | -5.636% | -44.393% |
| Rhythm Pharmaceuticals | -1.550% | 15.569% | 22.930% | 87.379% | 3.209% | 510.759% | 461.047% |
Comments
Cytokinetics (CYTK) was upgraded by UBS Group AG from "neutral" to "buy".
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its price target raised by Mizuho from $100.00 to $118.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for CYTK provided by MarketBeat
News
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYKORZO’s launch is outperforming expectations, with Cytokinetics saying early prescriptions
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK), exercised 15,000 options for common stock and immediately sold the resulting
